{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:55:48Z","timestamp":1790420148231,"version":"4.1.0"},"reference-count":41,"publisher":"Pharmaceutical Society of Japan","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2025,5,29]]},"DOI":"10.1248\/bpb.b24-00898","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T22:07:41Z","timestamp":1748470061000},"page":"721-727","source":"Crossref","is-referenced-by-count":3,"title":["Systemic mRNA Delivery into the Muscle of Duchenne Muscular Dystrophy Model Mice Using Alpha-Dystroglycan Binding Peptide Modified Lipid Nanoparticles"],"prefix":"10.1248","volume":"48","author":[{"given":"Eri","family":"Sasaki","sequence":"first","affiliation":[{"name":"Department of Drug Delivery and Molecular Biopharmaceutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432\u20131 Horinouchi, Hachioji, Tokyo 192\u20130392, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Itaya","sequence":"additional","affiliation":[{"name":"Department of Drug Delivery and Molecular Biopharmaceutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432\u20131 Horinouchi, Hachioji, Tokyo 192\u20130392, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Endo-Takahashi","sequence":"additional","affiliation":[{"name":"Department of Drug Delivery and Molecular Biopharmaceutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432\u20131 Horinouchi, Hachioji, Tokyo 192\u20130392, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Yano","sequence":"additional","affiliation":[{"name":"Department of Drug Delivery and Molecular Biopharmaceutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432\u20131 Horinouchi, Hachioji, Tokyo 192\u20130392, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhito","family":"Hamano","sequence":"additional","affiliation":[{"name":"Department of Drug Delivery and Molecular Biopharmaceutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432\u20131 Horinouchi, Hachioji, Tokyo 192\u20130392, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Hamada","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo 192\u20130392, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamato","family":"Kikkawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo 192\u20130392, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Nakashima","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432\u20131 Horinouchi, Hachioji, Tokyo 192\u20130392, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Tada","sequence":"additional","affiliation":[{"name":"Department of Drug Delivery and Molecular Biopharmaceutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432\u20131 Horinouchi, Hachioji, Tokyo 192\u20130392, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Miura","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432\u20131 Horinouchi, Hachioji, Tokyo 192\u20130392, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Design and Drug Disposition, Graduate School of Pharmaceutical Sciences, Tohoku University, 6\u20133 Aoba, Aramaki, Aoba-ku, Sendai 980\u20138578, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetaka","family":"Akita","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Design and Drug Disposition, Graduate School of Pharmaceutical Sciences, Tohoku University, 6\u20133 Aoba, Aramaki, Aoba-ku, Sendai 980\u20138578, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoyoshi","family":"Nomizu","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo 192\u20130392, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Negishi","sequence":"additional","affiliation":[{"name":"Department of Drug Delivery and Molecular Biopharmaceutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432\u20131 Horinouchi, Hachioji, Tokyo 192\u20130392, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Emery AEH. Population frequencies of inherited neuromuscular diseases-A world survey. <i>Neuromuscul. Disord.<\/i>, <b>1<\/b>, 19\u201329 (1991).","DOI":"10.1016\/0960-8966(91)90039-U"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Matsumura K, Campbell KP. Dystrophin-glycoprotein complex: its role in the molecular pathogenesis of muscular dystrophies. <i>Muscle Nerve<\/i>, <b>17<\/b>, 2\u201315 (1994).","DOI":"10.1002\/mus.880170103"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the duchenne muscular dystrophy locus. <i>Cell<\/i>, <b>51<\/b>, 919\u2013928 (1987).","DOI":"10.1016\/0092-8674(87)90579-4"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Lim KRQ, Maruyama R, Yokota T. Eteplirsen in the treatment of Duchenne muscular dystrophy. <i>Drug Des. Devel. Ther.<\/i>, <b>11<\/b>, 533\u2013545 (2017).","DOI":"10.2147\/DDDT.S97635"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Matsuo M, Masumura T, Nishio H, Nakajima T, Kitoh Y, Takumi T, Koga J, Nakamura H. Exon skipping during splicing of dystrophin mRNA precursor due to an intraexon deletion in the dystrophin gene of Duchenne muscular dystrophy kobe. <i>J. Clin. Invest.<\/i>, <b>87<\/b>, 2127\u20132131 (1991).","DOI":"10.1172\/JCI115244"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Nakamura A, Takeda S. Exon-skipping therapy for Duchenne muscular dystrophy. <i>Neuropathology<\/i>, <b>29<\/b>, 494\u2013501 (2009).","DOI":"10.1111\/j.1440-1789.2009.01028.x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Suzuki N, Hozumi K, Urushibata S, Yoshimura T, Kikkawa Y, Gumerson JD, Michele DE, Hoffman MP, Yamada Y, Nomizu M. Identification of \u03b1-dystroglycan binding sequences in the laminin <i>\u03b1<\/i>2 chain LG4-5 module. <i>Matrix Biol.<\/i>, <b>29<\/b>, 143\u2013151 (2010).","DOI":"10.1016\/j.matbio.2009.09.006"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Negishi Y, Nomizu M. Laminin-derived peptides: applications in drug delivery systems for targeting. <i>Pharmacol. Ther.<\/i>, <b>202<\/b>, 91\u201397 (2019).","DOI":"10.1016\/j.pharmthera.2019.05.017"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Sasaki E, Hayashi Y, Kimura Y, Sashida S, Hamano N, Nirasawa K, Hamada K, Katagiri F, Kikkawa Y, Sakai T, Yoshida A, Kawada M, Hirashima S, Miura T, Endo-Takahashi Y, Nomizu M, Negishi Y. Alpha-dystroglycan binding peptide A2G80-modified stealth liposomes as a muscle-targeting carrier for Duchenne muscular dystrophy. <i>J. Control. Release.<\/i>, <b>329<\/b>, 1037\u20131045 (2021).","DOI":"10.1016\/j.jconrel.2020.10.032"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Akita H, Ishiba R, Hatakeyama H, Tanaka H, Sato Y, Tange K, Arai M, Kubo K, Harashima H. A neutral envelope-type nanoparticle containing pH-responsive and SS-cleavable lipid-like material as a carrier for plasmid DNA. <i>Adv. Healthc. Mater.<\/i>, <b>2<\/b>, 1120\u20131125 (2013).","DOI":"10.1002\/adhm.201200431"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Akita H, Ishiba R, Togashi R, Tange K, Nakai Y, Hatakeyama H, Harashima H. A neutral lipid envelope-type nanoparticle composed of a pH-activated and vitamin E-scaffold lipid-like material as a platform for a gene carrier targeting renal cell carcinoma. <i>J. Control. Release.<\/i>, <b>200<\/b>, 97\u2013105 (2015).","DOI":"10.1016\/j.jconrel.2014.12.029"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Tanaka H, Oasa S, Kinjo M, Tange K, Nakai Y, Harashima H, Akita H. Temperature and pH sensitivity of a stabilized self-nanoemulsion formed using an ionizable lipid-like material <i>via<\/i> an oil-to-surfactant transition. <i>Colloids Surf. B Biointerfaces<\/i>, <b>151<\/b>, 95\u2013101 (2017).","DOI":"10.1016\/j.colsurfb.2016.11.020"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Tanaka H, Takahashi T, Konishi M, <i>et al<\/i>. Self-degradable lipid-like materials based on \u201cHydrolysis accelerated by the intra-particle enrichment of reactant (HyPER)\u201d for messenger RNA delivery. <i>Adv. Funct. Mater.<\/i>, <b>30<\/b>, 1910575 (2020).","DOI":"10.1002\/adfm.201910575"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Akita H. Development of an SS-cleavable pH-activated lipid-like material (ssPalm) as a nucleic acid delivery device. <i>Biol. Pharm. Bull.<\/i>, <b>43<\/b>, 1617\u20131625 (2020).","DOI":"10.1248\/bpb.b20-00534"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Tanaka H, Sakurai Y, Anindita J, Akita H. Development of lipid-like materials for RNA delivery based on intracellular environment-responsive membrane destabilization and spontaneous collapse. <i>Adv. Drug Deliv. Rev.<\/i>, <b>154-155<\/b>, 210\u2013226 (2020).","DOI":"10.1016\/j.addr.2020.07.001"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Cho R, Sakurai Y, Jones HS, Akita H, Hisaka A, Hatakeyama H. Silencing of VEGFR2 by RGD-modified lipid nanoparticles enhanced the efficacy of anti-PD-1 antibody by accelerating vascular normalization and infiltration of T cells in tumors. <i>Cancers<\/i> (Basel), <b>12<\/b>, 3630 (2020).","DOI":"10.3390\/cancers12123630"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Tanaka H, Takata N, Sakurai Y, Yoshida T, Inoue T, Tamagawa S, Nakai Y, Tange K, Yoshioka H, Maeki M, Tokeshi M, Akita H. Delivery of oligonucleotides using a self-degradable lipid-like material. <i>Pharmaceutics<\/i>, <b>13<\/b>, 544 (2021).","DOI":"10.3390\/pharmaceutics13040544"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Tanaka H, Miyama R, Sakurai Y, Tamagawa S, Nakai Y, Tange K, Yoshioka H, Akita H. Improvement of mRNA delivery efficiency to a T cell line by modulating PEG-lipid content and phospholipid components of lipid nanoparticles. <i>Pharmaceutics<\/i>, <b>13<\/b>, 2097 (2021).","DOI":"10.3390\/pharmaceutics13122097"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Sakurai Y, Abe N, Yoshikawa K, Oyama R, Ogasawara S, Murata T, Nakai Y, Tange K, Tanaka H, Akita H. Targeted delivery of lipid nanoparticle to lymphatic endothelial cells <i>via<\/i> anti-podoplanin antibody. <i>J. Control. Release<\/i>, <b>349<\/b>, 379\u2013387 (2022).","DOI":"10.1016\/j.jconrel.2022.06.052"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Kulkarni JA, Witzigmann D, Chen S, Cullis PR, Van Der Meel R. Lipid nanoparticle technology for clinical translation of siRNA therapeutics. <i>Acc. Chem. Res.<\/i>, <b>52<\/b>, 2435\u20132444 (2019).","DOI":"10.1021\/acs.accounts.9b00368"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Francia V, Schiffelers RM, Cullis PR, Witzigmann D. The biomolecular corona of lipid nanoparticles for gene therapy. <i>Bioconjug. Chem.<\/i>, <b>31<\/b>, 2046\u20132059 (2020).","DOI":"10.1021\/acs.bioconjchem.0c00366"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Suzuki T, Suzuki Y, Hihara T, Kubara K, Kondo K, Hyodo K, Yamazaki K, Ishida T, Ishihara H. PEG shedding-rate-dependent blood clearance of PEGylated lipid nanoparticles in mice: faster PEG shedding attenuates anti-PEG IgM production. <i>Int. J. Pharm.<\/i>, <b>588<\/b>, 119792 (2020).","DOI":"10.1016\/j.ijpharm.2020.119792"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Sakurai Y, Yoshikawa K, Arai K, Kazaoka A, Aoki S, Ito K, Nakai Y, Tange K, Furihata T, Tanaka H, Akita H. siRNA delivery to lymphatic endothelial cells <i>via<\/i> ApoE-mediated uptake by lipid nanoparticles. <i>J. Control. Release<\/i>, <b>353<\/b>, 125\u2013133 (2023).","DOI":"10.1016\/j.jconrel.2022.11.036"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Sato Y, Hatakeyama H, Sakurai Y, Hyodo M, Akita H, Harashima H. A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity <i>in vitro<\/i> and <i>in vivo<\/i>. <i>J. Control. Release.<\/i>, <b>163<\/b>, 267\u2013276 (2012).","DOI":"10.1016\/j.jconrel.2012.09.009"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Song LY, Ahkong QF, Rong Q, Wang Z, Ansell S, Hope MJ, Mui B. Characterization of the inhibitory effect of PEG-lipid conjugates on the intracellular delivery of plasmid and antisense DNA mediated by cationic lipid liposomes. <i>Biochim. Biophys. Acta<\/i>, <b>1558<\/b>, 1\u201313 (2002).","DOI":"10.1016\/S0005-2736(01)00399-6"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Nomizu M, Kim WH, Yamamura K, Utani A, Song SY, Otaka A, Roller PP, Kleinman HK, Yamada Y. Identification of cell binding sites in the laminin <i>\u03b1<\/i>1 chain carboxyl-terminal globular domain by systematic screening of synthetic peptides. <i>J. Biol. Chem.<\/i>, <b>270<\/b>, 20583\u201320590 (1995).","DOI":"10.1074\/jbc.270.35.20583"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Uster PS, Allen TM, Daniel BE, Mendez CJ, Newman MS, Zhu GZ. Insertion of poly(ethylene glycol) derivatized phospholipid into pre-formed liposomes results in prolonged <i>in vivo<\/i> circulation time. <i>FEBS Lett<\/i>, <b>386<\/b>, 243\u2013246 (1996).","DOI":"10.1016\/0014-5793(96)00452-8"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Moreira JN, Ishida T, Gaspar R, Allen TM. Use of the post-insertion technique to insert peptide ligands into pre-formed stealth liposomes with retention of binding activity and cytotoxicity. <i>Pharm. Res.<\/i>, <b>19<\/b>, 265\u2013269 (2002).","DOI":"10.1023\/A:1014434732752"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Ambegia E, Ansell S, Cullis P, Heyes J, Palmer L, MacLachlan I. Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression. <i>Biochim. Biophys. Acta<\/i>, <b>1669<\/b>, 155\u2013163 (2005).","DOI":"10.1016\/j.bbamem.2005.02.001"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Mojumdar K, Liang F, Giordano C, Lemaire C, Danialou G, Okazaki T, Bourdon J, Rafei M, Galipeau J, Divangahi M, Petrof BJ. Inflammatory monocytes promote progression of Duchenne muscular dystrophy and can be therapeutically targeted <i>via<\/i> CCR2. <i>EMBO Mol. Med.<\/i>, <b>6<\/b>, 1476\u20131492 (2014).","DOI":"10.15252\/emmm.201403967"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Miyatake S, Shimizu-Motohashi Y, Takeda S, Aoki Y. Anti-inflammatory drugs for duchenne muscular dystrophy: focus on skeletal muscle-releasing factors. <i>Drug Des. Devel. Ther.<\/i>, <b>10<\/b>, 2745\u20132758 (2016).","DOI":"10.2147\/DDDT.S110163"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A. Duchenne muscular dystrophy. <i>Nat. Rev. Dis. Primers<\/i>, <b>7<\/b>, 13 (2021).","DOI":"10.1038\/s41572-021-00248-3"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Szwec S, Kap\u0142ucha Z, Chamberlain JS, Konieczny P. Dystrophin- and utrophin-based therapeutic approaches for treatment of duchenne muscular dystrophy: a comparative review. <i>BioDrugs<\/i>, <b>38<\/b>, 95\u2013119 (2024).","DOI":"10.1007\/s40259-023-00632-3"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Matsuda R, Nishikawa A, Tanaka H. Visualization of dystrophic muscle fibers in Mdx mouse by vital staining with evans blue: evidence of apoptosis in dystrophin-deficient muscle. <i>J. Biochem.<\/i>, <b>118<\/b>, 959\u2013963 (1995).","DOI":"10.1093\/jb\/118.5.959"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Hamer PW, McGeachie JM, Davies MJ, Grounds MD. Evans blue dye as an <i>in vivo<\/i> marker of myofibre damage: optimising parameters for detecting initial myofibre membrane permeability. <i>J. Anat.<\/i>, <b>200<\/b>, 69\u201379 (2002).","DOI":"10.1046\/j.0021-8782.2001.00008.x"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Barresi R, Campbell KP. Dystroglycan: from biosynthesis to pathogenesis. <i>J. Cell Sci.<\/i>, <b>119<\/b>, 199\u2013207 (2006).","DOI":"10.1242\/jcs.02814"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Sharpe KM, Premsukh MD, Townsend D. Alterations of dystrophin associated glycoproteins in the heart lacking dystrophin or dystrophin and utrophin. <i>J. Muscle Res. Cell Motil.<\/i>, <b>34<\/b>, 395\u2013405 (2013).","DOI":"10.1007\/s10974-013-9362-9"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Roshmi RR, Yokota T. Viltolarsen: from preclinical studies to FDA approval. <i>Methods Mol. Biol.<\/i>, <b>2587<\/b>, 31\u201341 (2023).","DOI":"10.1007\/978-1-0716-2772-3_2"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Futaki S, Suzuki T, Ohashi W, Yagami T, Tanaka S, Ueda K, Sugiura Y. Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. <i>J. Biol. Chem.<\/i>, <b>276<\/b>, 5836\u20135840 (2001).","DOI":"10.1074\/jbc.M007540200"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Iwasa A, Akita H, Khalil I, Kogure K, Futaki S, Harashima H. Cellular uptake and subsequent intracellular trafficking of R8-liposomes introduced at low temperature. <i>Biochim. Biophys. Acta<\/i>, <b>1758<\/b>, 713\u2013720 (2006).","DOI":"10.1016\/j.bbamem.2006.04.015"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Wang X, Huang H, Zhang L, Bai Y, Chen H. PCM and TAT co-modified liposome with improved myocardium delivery: <i>in vitro<\/i> and <i>in vivo<\/i> evaluations. <i>Drug Deliv.<\/i>, <b>24<\/b>, 339\u2013345 (2017).","DOI":"10.1080\/10717544.2016.1253121"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/5\/48_b24-00898\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T03:33:56Z","timestamp":1748662436000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/5\/48_b24-00898\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b24-00898","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,29]]},"article-number":"b24-00898"}}